Clovis Oncology Aktie [WKN DE: A1JPJY / ISIN: US1894641000]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Clovis Oncology Inc.

12.12.22		Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286 (Businesswire)
27.10.22		Clovis Oncology Presents Data from TRITON3 Phase 3 Trial of Rubraca® (rucaparib) at the 29th Annual Prostate Cancer Foundation Scientific Retreat (Businesswire)
17.10.22		Clovis Oncology Highlights Updated LuMIERE Phase 1 Data of Targeted Radiotherapy Candidate FAP-2286 at the 35th Annual EANM Congress (Businesswire)
03.10.22		TRITON3 Phase 3 Trial of Rubraca® (rucaparib) Achieves Primary Endpoint in Men with Metastatic Castration-Resistant Prostate Cancer with BRCA or ATM Mutations (Businesswire)
21.09.22		Clovis Oncology and Isotopia Announce Lutetium-177 Clinical Supply Agreement (Businesswire)
13.09.22		Clovis Oncology Submits Applications for Rubraca® Label Expansion in the US and European Union as First-line Maintenance Treatment in Women with Advanced Ovarian Cancer (Businesswire)
11.09.22		Clovis Oncology’s Rubraca® (Rucaparib) as First-Line Maintenance Treatment Improves Progression-Free Survival in Women with Advanced Ovarian Cancer Across Disease Risk Subgroups (Businesswire)
08.08.22		Clovis Oncology Announces Second Quarter 2022 Operating Results and Provides Update on Clinical Development Programs (Businesswire)
20.07.22		Clovis Oncology to Announce Second Quarter 2022 Financial Results and Host Webcast Conference Call on August 8 (Businesswire)
14.06.22		Clovis Oncology Highlights Phase 1 Data from Ongoing Clinical Studies of Targeted Radiotherapy Candidate FAP-2286 at SNMMI Annual Meeting (Businesswire)
14.06.22		Pre-market Movers: KAVL, SLNO, IRM, HST, VUZI… (RTTNews)
05.05.22		Clovis Oncology to Present at the BofA Securities 2022 Healthcare Conference (Businesswire)
04.05.22		Clovis Oncology Announces First Quarter 2022 Operating Results and Provides Update on Clinical Development Programs (Businesswire)
28.04.22		Clovis Oncology Highlights Rubraca® (Rucaparib) and FAP-2286 Data to be Presented at 2022 ASCO Annual Meeting (Businesswire)
20.04.22		Clovis Oncology to Announce First Quarter 2022 Financial Results and Host Webcast Conference Call on May 4 (Businesswire)
08.04.22		Clovis Oncology Highlights Presentations on FAP-2286 and Rubraca® (Rucaparib) at the AACR Annual Meeting 2022 (Businesswire)
16.03.22		Clovis Oncology and Evergreen Theragnostics Initiate Development and Manufacturing Services Agreement for Actinium-225-Labeled FAP-2286 (Businesswire)
23.02.22		Clovis Oncology Announces 2021 Operating Results and Anticipated 2022 Development Milestones (Businesswire)
10.02.22		Clovis Oncology to Announce Fourth Quarter 2021 and Year End 2021 Financial Results and Host Webcast Conference Call (Businesswire)
10.01.22		Clovis Oncology Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2021 (Businesswire)
28.06.21		Initial Clinical Experience of FAP-2286 in Independent Named Patient Use Published in The Journal of Nuclear Medicine (Businesswire)
23.06.21		Clovis Oncology Announces LuMIERE Clinical Trial Evaluating Novel Peptide-Targeted Radionuclide Therapy FAP-2286 Now Open for Enrollment (Businesswire)
10.06.21		Clovis Oncology Announces Partial Adjournment of Annual Meeting of Stockholders (Businesswire)
20.05.21		Clovis Oncology Highlights Rubraca® (rucaparib) and Lucitanib Data at 2021 ASCO Annual Meeting (Businesswire)
17.05.21		Clovis Oncology Announces At-The-Market Equity Offering Program (Businesswire)
05.05.21		Clovis Oncology Announces First Quarter 2021 Operating Results (Businesswire)
28.04.21		Clovis Oncology to Present at the Bank of America 2021 Health Care Conference (Businesswire)
21.04.21		Clovis Oncology to Announce First Quarter 2021 Financial Results and Host Webcast Conference Call on May 5 (Businesswire)
10.04.21		Clovis Oncology Highlights Rubraca® (rucaparib) Clinical Data at AACR Virtual Annual Meeting 2021 (Businesswire)
19.03.21		Clovis Oncology’s Rubraca® (rucaparib) Significantly Improves Progression-Free Survival versus Chemotherapy in Patients with Later-line Ovarian Cancer Associated with a BRCA Mutation (Businesswire)
17.02.21		Clovis Oncology to Announce Fourth Quarter and Year-End 2020 Financial Results and Host Webcast Conference Call on February 23 (Businesswire)
11.02.21		Clovis Oncology Presents Data in Advanced Prostate Cancer at ASCO 2021 Genitourinary Cancers Symposium Virtual Meeting (Businesswire)
04.02.21		Clovis Oncology to Highlight Data at ASCO 2021 Genitourinary Cancers Symposium Virtual Meeting (Businesswire)
11.01.21		Clovis Oncology Announces Preliminary Product Revenues for the Fourth Quarter and Full Year 2020 (Businesswire)
29.12.20		Clovis Oncology Submits Investigational New Drug Applications for Novel Peptide-Targeted Radionuclide FAP-2286 for Therapeutic and Imaging Clinical Trial (Businesswire)
25.11.20		Clovis Oncology Announces Exercise by Existing Holder of Option to Purchase an Additional $7.5 Million Aggregate Principal Amount of the Company’s 4.50% Convertible Senior Notes Due 2024 (Businesswire)
20.11.20		Clovis Oncology to Present at the Piper Sandler 32nd Annual Healthcare Conference (Businesswire)
05.11.20		Clovis Oncology Announces Third Quarter 2020 Operating Results (Businesswire)
05.11.20		Clovis Oncology Announces Debt Exchange Transaction and Offering of Convertible Senior Notes (Businesswire)
20.10.20		Clovis Oncology to Announce Third Quarter 2020 Financial Results and Host Webcast Conference Call on November 5 (Businesswire)
15.10.20		Pre-market Movers In Healthcare Sector: ORGO, NMRD, NK, CYCN... (RTTNews)
17.09.20		New Data Presented at ESMO Virtual Congress 2020 Highlight Breadth and Potential of Clovis Oncology Products and Pipeline (Businesswire)
10.09.20		Clovis Oncology Announces Oral Plenary Session Presentation at International Gynecologic Cancer Society (IGCS) Digital Annual Global Meeting (Businesswire)
09.09.20		Clovis Oncology to Highlight Data for its Three Portfolio Compounds at the ESMO Virtual Congress 2020 (Businesswire)
08.09.20		Clovis Oncology to Present at the H.C. Wainwright 22nd Annual Global Investment Conference (Businesswire)
27.08.20		Pre-market Movers In Healthcare Sector: EYPT, CLVS, ABT, VBIV, LPCN... (RTTNews)
27.08.20		FDA Approves FoundationOne® Liquid CDx to Serve as Rubraca® (rucaparib) Companion Diagnostic to Identify Eligible Patients with BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (mCRPC) (Businesswire)
17.08.20		Journal of Clinical Oncology Publishes Additional Data from Clovis Oncology’s TRITON2 Clinical Trial Evaluating Rubraca® (rucaparib) for the Treatment of mCRPC in Patients with BRCA1/2 Gene Mutations (Businesswire)
06.08.20		Clovis Oncology Announces Second Quarter 2020 Operating Results (Businesswire)
05.08.20		Clovis Oncology Announces First Patient Enrolled in the Phase 2 Portion of the LIO-1 Trial Evaluating the Combination of Lucitanib and Opdivo in Gynecologic Cancers (Businesswire)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

Solana Kurs Prognose: Jetzt einsteigen und Millionär werden?

Pierer Mobility-Aktie mit zweistelligem Kurssprung: KTM AG wird fortgeführt - Eigenverwaltung bleibt

Bullishe Aussichten: Das erwartet JPMorgan für den Goldpreis in 2025

Mayr-Melnhof startet im kommenden Jahr Aktienrückkauf - Aktie gewinnt deutlich

Lilium-Aktie zündet Kursrakete: Lilium kann neuen Investor von sich überzeugen

Bitcoin Kurs Prognose: BTC verliert 10 Prozent, jetzt schnell verkaufen?

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	26.12.2024 20:34
Kaufwert:	EUR
	Hinzufügen Speichern